Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis
Van De Laar, Celine J, Oude Voshaar, Martijn A H, Fakhouri, Walid K H, Zaremba-Pechmann, Liliana, De Leonardis, Francesco, De La Torre, Inmaculada, Van De Laar, Mart A F J
Published in ClinicoEconomics and outcomes research (01.01.2020)
Published in ClinicoEconomics and outcomes research (01.01.2020)
Get full text
Journal Article